NTRA: natera.com Price/Earnings to Growth Multiple

Corporate company logo of Natera, Inc. (NTRA)

Innovative genetic analysis systems in oncology and reproduction are experiencing a rapid surge. The valuation adequacy ratio relative to growth rates indicates that the metric has reached the level of 0.00. Dominance in prenatal diagnostics and insurance coverage ensure stable FCF. The advantage of Natera, Inc. (NTRA) is based on unique genomic data sets that create a sustainable cash flow.

NTRA - Natera Corp PEG Multiple over the range 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for Natera, Inc. (NTRA)

- stock value and consensus price forecast:
Stock Price Natera Inc|NTRA - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Natera Corp|NTRA - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Price of a Share Natera|NTRA - Book Capitalization|Market Capitalization to Book Value natera.com|NTRA - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Capital Natera, Inc.|NTRA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio natera.com|NTRA - Company Debts|Debt to Book Value Ratio Natera Corp|NTRA - Company Long-Term Debts|Company Short-Term Debts Natera|Intermediate Liquidity Ratio natera.com
- earnings and market ratios statistics:
NTRA - Net Profit|Expected Net Profit Natera, Inc.|NTRA - Price to Earnings Ratio|Future Price to Earnings Multiple Natera Medical|NTRA - PEG Multiple|EV/EBITDA Multiple Natera Corp|NTRA - Operating profit before deduction of amortization|Earnings per share for the trailing year Natera|NTRA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months natera.com|NTRA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Natera, Inc.
Fundamental company analysis:Natera Inc (NTRA)
Mass-produced product of Natera Inc

The PEG ratio compares the P/E multiple with earnings growth, identifying an undervalued asset when the value is below one. An analysis of the P/E valuation relative to business expansion rates confirms the potential of Natera, Inc. (NTRA), as unique patented oncology diagnostic methods create a high barrier to entry, allowing the company to exercise pricing power with insurance providers and accelerate earnings growth.

Competing companies

PEG Multiple Humacyte Inc (HUMA)|PEG Multiple SERA (Sera Prognostics, Inc.)